Generic placeholder image

Anti-Cancer Agents in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1871-5206
ISSN (Online): 1875-5992

Mini-Review Article

Cardiotoxicity of Targeted Therapies in Children with Haematological Malignancies and Solid Tumors

Author(s): Athanasios Bangeas and Athanasios Tragiannidis*

Volume 23, Issue 15, 2023

Published on: 09 June, 2023

Page: [1702 - 1709] Pages: 8

DOI: 10.2174/1871520623666230525162147

Price: $65

Open Access Journals Promotions 2
Abstract

Cardiotoxicity represents an important acute or chronic adverse event of treatment modalities for childhood cancer. In the last two decades the emergence of novel cancer therapies has aimed to increase unaided or mostly in combination with conventional chemotherapy for the survival rates of pediatric cancer especially for those patients with relapsed and/or refractory disease. The use of emerging targeted therapies in combination with conventional chemotherapy is related to cardiovascular adverse events mostly reported in adults. The aim of our short review was to investigate the cardiotoxic side effects of targeted chemotherapeutic agents as monoclonal antibodies and small molecules in pediatric cancer patients.

Keywords: Cardiotoxicity, children, cancer, monoclonal antibodies, small molecules, pediatric cancer.

Graphical Abstract
[1]
Steliarova-Foucher, E.; Colombet, M.; Ries, L.A.G.; Moreno, F.; Dolya, A.; Bray, F.; Hesseling, P.; Shin, H.Y.; Stiller, C.A.; Bouzbid, S.; Hamdi-Cherif, M.; Hablas, A.; Chirpaz, E.; Buziba, N.; Chesumbai, G.C.; Manraj, S.S.; Reynders, D.; Wabinga, H.R.; Chokunonga, E.; Moreno, F.; Lima, C.A.; Asturian, L.C.; de Oliveira, J.C.; de Aquino, J.A.P.; Gallagher, S.M.V.; Uribe, C.J.; Bravo, L.E.; Yepez, C.M.C.; Torres, A.G.; Galán, A.Y.H.; Martinez, R.F.C.; Castillo, C.J.C.; Mendoza, A.M.; Cueva, A.P.; Hanchard, B.; Fajardo-Gutiérrez, A.; Zavala Zegarra, D.E.; Barrios, E.; Nikiforuk, C.; Woods, R.; Turner, D.; MacIntyre, M.; Corriveau, A.; Navaneelan, T.; Bertrand, C.; Stuart-Panko, H.; Wilson, R.J.; Kosary, C.; Shen, X.; Brockhouse, J.; Yee, G.A.; Mitchell, T.C.; Snipes, K.; West, D.; Rao, C.; Bolick, S.; Rycroft, R.K.; Mueller, L.; Zheng, Y.; Dosch, K.; Brown, H.; Vargas, A.; Levin, G.M.; Bayakly, R.; Johnson, C.; Shen, T.; Ruppert, L.; Lynch, C.F.; Lai, S.M.; Tucker, T.C.; Wu, X.C.; Schwenn, M.; Stern, K.; Gershman, S.; Copeland, G.; Bushhouse, S.; Rogers, D.B.; Jackson Thompson, J.; Lemons, D.; Frederick, S.; Harris, J.A.; Riddle, B.; Stroup, A.; Wiggins, C.; Schymura, M.J.; Giljahn, L.K.; Sheikh, A.; Schubert, S.; Aldinger, W.; Fulton, J.P.; Whiteside, M.; Nogueira, L.; Sweeney, C.; Johnson, A.; Martin, J.; Farley, S.; Harrelson, D.; Malicki, R.; Espinoza, J.R.; Hernandez, B.Y.; Abulfateh, N.; Wang, N.; Ngan, R.K.C.; Lingegowda, K.B.; Swaminathan, R.; Koyande, S.S.; Silverman, B.; Ozasa, K.; Kanemura, S.; Soda, M.; Miyashiro, I.; Shibata, A.; Nimri, O.; Won, Y.J.; Kim, C.H.; Hong, N.S.; Nam, H.S.; Kweon, S.; Kim, W.C.; Huh, J.S.; Jung, K.W.; Yoo, C.I.; Elbasmy, A.; Laudico, A.V.; Lumague, M.R.; AlMutlag, H.; Buasom, R.; Srisukho, S.; Tanabodee, J.; Wiangnon, S.; Pongnikorn, D.; Sriplung, H.; Dirican, O.; Eser, S.; Le Hoang, M.; Hackl, M.; Zborovskaya, A.; Dimitrova, N.; Valerianova, Z.; Sekerija, M.; Pavlou, P.; Dušek, M.; Mägi, M.; Clavel, J.; Lacour, B.; Guizard, A.V.; Bouvier, V.; Troussard, X.; Woronoff, A.S.; Tretarre, B.; Colonna, M.; Molinié, F.; Bara, S.; Velten, M.; Marrer, E.; Ganry, O.; Grosclaude, P.; Kaatsch, P.; Zeissig, S.R.; Holleczek, B.; Katalinic, A.; Jakab, Z.; Birgisson, H.; Walsh, P.M.; Mangone, L.; Merletti, F.; Magoni, M.; Mangone, L.; Ferretti, S.; Serraino, D.; Spagnoli, G.; Fusco, M.; Michiara, M.; Tumino, R.; Falcini, F.; Sensi, F.; Tisano, F.; Piffer, S.; Stracci, F.; Tagliabue, G.; Smailyte, G.; Agius, D.; Visser, O.; Ursin, G.; Didkowska, J.; Trojanowski, M.; Wojciechowska, U.; Forjaz de Lacerda, G.; Silva, M.A.; Laranja, P.J.; da Costa Miranda, A.; Kaiserova, E.; Primic, Ž.M.; Peris-Bonet, R.; Vicente, R.M.L.; Almar, M.E.; Quirós, G. J.R.; Ramos, M.M.; Errezola Saizar, M.; Alemán Herrera, A.; Díaz, G.J.M.; Marcos-Gragera, R.; Sanchez-Perez, M.J.; Ardanaz, A.E.; Galceran, J.; Klint, A.; Kuehni, C.E.; Bouchardy, C.; Levi, F.; Bordoni, A.; Konzelmann, I.; Rohrmann, S.; Stiller, C.A.; Gavin, A.T.; Brewster, D.H.; Phung, H.; Rushton, S.; Guthridge, S.; Aitken, J.; D’Onise, K.; Venn, A.; Farrugian, H.; Threlfall, T.J.; Laumond, S.; Yen Kai Sun, L.; Hendrix, J.; Ballantine, K.; Colombet, M.; Dolya, A.; Masuyer, E.; Steliarova-Foucher, E. International incidence of childhood cancer, 2001–10: a population-based registry study. Lancet Oncol., 2017, 18(6), 719-731.
[http://dx.doi.org/10.1016/S1470-2045(17)30186-9] [PMID: 28410997]
[2]
Sherry, L.M.; Xu, J.; Kochanek, K.D.; Arias, E.; Tejada-Vera, B. Deaths: Final Data for 2018. National Vital Statistics Reports, 2018, 69(13)
[3]
Howlader, N.; Noone, A.M.; Krapcho, M. SEER Cancer Statistics Review, 1975–2013; National Cancer Institute: Bethesda, MD, 2016.
[4]
Mertens, A.C.; Liu, Q.; Neglia, J.P.; Wasilewski, K.; Leisenring, W.; Armstrong, G.T.; Robison, L.L.; Yasui, Y. Cause-specific late mortality among 5-year survivors of childhood cancer: The childhood cancer survivor study. J. Natl. Cancer Inst., 2008, 100(19), 1368-1379.
[http://dx.doi.org/10.1093/jnci/djn310] [PMID: 18812549]
[5]
Oeffinger, K.C.; Mertens, A.C.; Sklar, C.A. Chronic health conditions in adult survivors of childhood cancer. Oncol. Times, 2007, 29(1), 26.
[http://dx.doi.org/10.1097/01.COT.0000265629.30194.8e]
[6]
Mulrooney, D.A.; Yeazel, M.W.; Kawashima, T.; Mertens, A.C.; Mitby, P.; Stovall, M.; Donaldson, S.S.; Green, D.M.; Sklar, C.A.; Robison, L.L.; Leisenring, W.M. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ, 2009, 339(1), b4606.
[http://dx.doi.org/10.1136/bmj.b4606] [PMID: 19996459]
[7]
Armstrong, G.T.; Chen, Y.; Yasui, Y.; Leisenring, W.; Gibson, T.M.; Mertens, A.C.; Stovall, M.; Oeffinger, K.C.; Bhatia, S.; Krull, K.R.; Nathan, P.C.; Neglia, J.P.; Green, D.M.; Hudson, M.M.; Robison, L.L. Reduction in late mortality among 5-year survivors of childhood cancer. N. Engl. J. Med., 2016, 374(9), 833-842.
[http://dx.doi.org/10.1056/NEJMoa1510795] [PMID: 26761625]
[8]
Gibson, T.M.; Mostoufi-Moab, S.; Stratton, K.L.; Barnea, D.; Chow, E.J.; Donaldson, S.S.; Howell, R.M.; Hudson, M.M.; Leisenring, W.M.; Mahajan, A.; Nathan, P.C.; Ness, K.K.; Sklar, C.A.; Tonorezos, E.S.; Weldon, C.B.; Wells, E.M.; Yasui, Y.; Armstrong, G.T.; Robison, L.L.; Oeffinger, K.C. Temporal patterns in the risk of chronic health conditions among survivors of childhood cancer diagnosed 1970-1999: A report from the childhood cancer survivor study. Lancet Oncol., 2018, 19(12), 1590-1601.
[9]
Mulrooney, D.A.; Armstrong, G.T.; Huang, S.; Ness, K.K.; Ehrhardt, M.J.; Joshi, V.M.; Plana, J.C.; Soliman, E.Z.; Green, D.M.; Srivastava, D.; Santucci, A.; Krasin, M.J.; Robison, L.L.; Hudson, M.M. Cardiac outcomes in adult survivors of childhood cancer exposed to cardiotoxic therapy. Ann. Intern. Med., 2016, 164(2), 93-101.
[http://dx.doi.org/10.7326/M15-0424] [PMID: 26747086]
[10]
Hunt, S.A.; Abraham, W.T.; Chin, M.H.; Feldman, A.M.; Francis, G.S.; Ganiats, T.G.; Jessup, M.; Konstam, M.A.; Mancini, D.M. Focused update incorporated into the ACC/AHA 2005 Guidelines for the diagnosis and management of heart failure in adults. Circulation, 2009, 119, e391-e479.
[11]
Denlinger, C.S.; Sanft, T.; Baker, K.S.; Broderick, G.; Demark-Wahnefried, W.; Friedman, D.L.; Goldman, M.; Hudson, M.; Khakpour, N.; King, A.; Koura, D.; Lally, R.M.; Langbaum, T.S.; McDonough, A.L.; Melisko, M.; Montoya, J.G.; Mooney, K.; Moslehi, J.J.; O’Connor, T.; Overholser, L.; Paskett, E.D.; Peppercorn, J.; Pirl, W.; Rodriguez, M.A.; Ruddy, K.J.; Silverman, P.; Smith, S.; Syrjala, K.L.; Tevaarwerk, A.; Urba, S.G.; Wakabayashi, M.T.; Zee, P.; McMillian, N.R.; Freedman-Cass, D.A. Survivorship, Version 2.2018, NCCN clinical practice guidelines in oncology. J. Natl. Compr. Canc. Netw., 2018, 16(10), 1216-1247.
[http://dx.doi.org/10.6004/jnccn.2018.0078] [PMID: 30323092]
[12]
Lipshultz, S.E.; Adams, M.J.; Colan, S.D.; Constine, L.S.; Herman, E.H.; Hsu, D.T.; Hudson, M.M.; Kremer, L.C.; Landy, D.C.; Miller, T.L.; Oeffinger, K.C.; Rosenthal, D.N.; Sable, C.A.; Sallan, S.E.; Singh, G.K.; Steinberger, J.; Cochran, T.R.; Wilkinson, J.D. Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association. Circulation, 2013, 128(17), 1927-1995.
[http://dx.doi.org/10.1161/CIR.0b013e3182a88099] [PMID: 24081971]
[13]
Ryan, T.D.; Nagarajan, R.; Godown, J. Cardiovascular toxicities in pediatric cancer survivors. Cardiol. Clin., 2019, 37(4), 533-544.
[http://dx.doi.org/10.1016/j.ccl.2019.07.002] [PMID: 31587793]
[14]
Moslehi, J.J. Cardiovascular toxic effects of targeted cancer therapies. N. Engl. J. Med., 2016, 375(15), 1457-1467.
[http://dx.doi.org/10.1056/NEJMra1100265] [PMID: 27732808]
[15]
Neilan, T.G.; Rothenberg, M.L.; Amiri-Kordestani, L.; Sullivan, R.J.; Steingart, R.M.; Gregory, W.; Hariharan, S.; Hammad, T.A.; Lindenfeld, J.; Murphy, M.J.; Moslehi, J.J. Myocarditis associated with immune checkpoint inhibitors: an expert consensus on data gaps and a call to action. Oncologist, 2018, 23(8), 874-878.
[http://dx.doi.org/10.1634/theoncologist.2018-0157] [PMID: 29802220]
[16]
Kantarjian, H.M.; DeAngelo, D.J.; Stelljes, M.; Martinelli, G.; Liedtke, M.; Stock, W.; Gökbuget, N.; O’Brien, S.; Wang, K.; Wang, T.; Paccagnella, M.L.; Sleight, B.; Vandendries, E.; Advani, A.S. Inotuzumab Ozogamicin versus standard therapy for acute lymphoblastic leukemia. N. Engl. J. Med., 2016, 375(8), 740-753.
[http://dx.doi.org/10.1056/NEJMoa1509277] [PMID: 27292104]
[18]
Pennesi, E.; Michels, N.; Brivio, E.; van der Velden, V.H.J.; Jiang, Y.; Thano, A.; Ammerlaan, A.J.C.; Boer, J.M.; Beverloo, H.B.; Sleight, B.; Chen, Y.; Vormoor-Bürger, B.; Rives, S.; Bielorai, B.; Rössig, C.; Petit, A.; Rizzari, C.; Engstler, G.; Starý, J.; Bautista Sirvent, F.J.; Chen-Santel, C.; Bruno, B.; Bertrand, Y.; Rialland, F.; Plat, G.; Reinhardt, D.; Vinti, L.; Von Stackelberg, A.; Locatelli, F.; Zwaan, C.M. Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: Results from a phase II trial. Leukemia, 2022, 36(6), 1516-1524.
[http://dx.doi.org/10.1038/s41375-022-01576-3] [PMID: 35468945]
[19]
O’Brien, M.M.; Ji, L.; Shah, N.N.; Rheingold, S.R.; Bhojwani, D.; Yuan, C.M.; Xu, X.; Yi, J.S.; Harris, A.C.; Brown, P.A.; Borowitz, M.J.; Militano, O.; Kairalla, J.; Devidas, M.; Raetz, E.A.; Gore, L.; Loh, M.L.; Phase, I.I.; Phase, I.I. Trial of Inotuzumab Ozogamicin in children and adolescents with relapsed or refractory B-cell acute lymphoblastic leukemia: Children’s oncology group protocol AALL1621. J. Clin. Oncol., 2022, 40(9), 956-967.
[http://dx.doi.org/10.1200/JCO.21.01693] [PMID: 35007127]
[20]
Giudice, V.; Vecchione, C.; Selleri, C. Cardiotoxicity of novel targeted hematological therapies. Life, 2020, 10(12), 344.
[http://dx.doi.org/10.3390/life10120344] [PMID: 33322351]
[21]
Silva, P.N.; Valente, P.M.S.; Castilho, S.R. Monoclonal-induced cardiotoxicity in patients with non-Hodgkin’s lymphoma and breast cancer: A retrospective study in an oncology clinic. J. Oncol. Pharm. Pract., 2022.
[http://dx.doi.org/10.1177/10781552221098426] [PMID: 35542978]
[23]
McAtee, C.L.; Lubega, J.; Underbrink, K.; Curry, K.; Msaouel, P.; Barrow, M.; Muscal, E.; Lotze, T.; Srivaths, P.; Forbes, L.R.; Allen, C.; Bernhardt, M.B. Association of Rituximab use with adverse events in children, adolescents, and young adults. JAMA Netw. Open, 2021, 4(2), e2036321.
[http://dx.doi.org/10.1001/jamanetworkopen.2020.36321] [PMID: 33533931]
[24]
Darvishi, B.; Farahmand, L.; Jalili, N.; Majidzadeh-A, K. Blinatumomab provoked fatal heart failure. Int. Immunopharmacol., 2016, 41, 42-46.
[http://dx.doi.org/10.1016/j.intimp.2016.10.017] [PMID: 27816725]
[25]
Mahadeo, K.M.; Khazal, S.J.; Abdel-Azim, H.; Fitzgerald, J.C.; Taraseviciute, A.; Bollard, C.M.; Tewari, P.; Duncan, C.; Traube, C.; McCall, D.; Steiner, M.E.; Cheifetz, I.M.; Lehmann, L.E.; Mejia, R.; Slopis, J.M.; Bajwa, R.; Kebriaei, P.; Martin, P.L.; Moffet, J.; McArthur, J.; Petropoulos, D.; O’Hanlon Curry, J.; Featherston, S.; Foglesong, J.; Shoberu, B.; Gulbis, A.; Mireles, M.E.; Hafemeister, L.; Nguyen, C.; Kapoor, N.; Rezvani, K.; Neelapu, S.S.; Shpall, E.J. Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network. Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy. Nat. Rev. Clin. Oncol., 2019, 16(1), 45-63.
[http://dx.doi.org/10.1038/s41571-018-0075-2] [PMID: 30082906]
[26]
Grupp, S.A.; Kalos, M.; Barrett, D.; Aplenc, R.; Porter, D.L.; Rheingold, S.R.; Teachey, D.T.; Chew, A.; Hauck, B.; Wright, J.F.; Milone, M.C.; Levine, B.L.; June, C.H. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med., 2013, 368(16), 1509-1518.
[http://dx.doi.org/10.1056/NEJMoa1215134] [PMID: 23527958]
[27]
Maude, S.L.; Frey, N.; Shaw, P.A.; Aplenc, R.; Barrett, D.M.; Bunin, N.J.; Chew, A.; Gonzalez, V.E.; Zheng, Z.; Lacey, S.F.; Mahnke, Y.D.; Melenhorst, J.J.; Rheingold, S.R.; Shen, A.; Teachey, D.T.; Levine, B.L.; June, C.H.; Porter, D.L.; Grupp, S.A. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med., 2014, 371(16), 1507-1517.
[http://dx.doi.org/10.1056/NEJMoa1407222] [PMID: 25317870]
[28]
June, C.H.; Sadelain, M. Chimeric antigen receptor therapy. N. Engl. J. Med., 2018, 379(1), 64-73.
[http://dx.doi.org/10.1056/NEJMra1706169] [PMID: 29972754]
[29]
Chen, Z.I.; Ai, D.I. Cardiotoxicity associated with targeted cancer therapies. Mol. Clin. Oncol., 2016, 4(5), 675-681.
[http://dx.doi.org/10.3892/mco.2016.800] [PMID: 27123262]
[30]
Wang, J.; Mou, N.; Yang, Z.; Li, Q.; Jiang, Y.; Meng, J.; Liu, X.; Deng, Q. Efficacy and safety of humanized anti‐CD19‐CAR‐T therapy following intensive lymphodepleting chemotherapy for refractory/relapsed B acute lymphoblastic leukaemia Br. J. Haematol., 2020, 191(2), 212-222.
[http://dx.doi.org/10.1111/bjh.16623] [PMID: 32232846]
[31]
Ganatra, S.; Parikh, R.; Neilan, T.G. Cardiotoxicity of immune therapy. Cardiol. Clin., 2019, 37(4), 385-397.
[http://dx.doi.org/10.1016/j.ccl.2019.07.008] [PMID: 31587780]
[32]
Pathan, N.; Hemingway, C.A.; Alizadeh, A.A.; Stephens, A.C.; Boldrick, J.C.; Oragui, E.E.; McCabe, C.; Welch, S.B.; Whitney, A.; O’Gara, P.; Nadel, S.; Relman, D.A.; Harding, S.E.; Levin, M. Role of interleukin 6 in myocardial dysfunction of meningococcal septic shock. Lancet, 2004, 363(9404), 203-209.
[http://dx.doi.org/10.1016/S0140-6736(03)15326-3] [PMID: 14738793]
[33]
Lee, D.W.; Santomasso, B.D.; Locke, F.L.; Ghobadi, A.; Turtle, C.J.; Brudno, J.N.; Maus, M.V.; Park, J.H.; Mead, E.; Pavletic, S.; Go, W.Y.; Eldjerou, L.; Gardner, R.A.; Frey, N.; Curran, K.J.; Peggs, K.; Pasquini, M.; DiPersio, J.F.; van den Brink, M.R.M.; Komanduri, K.V.; Grupp, S.A.; Neelapu, S.S. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol. Blood Marrow Transplant., 2019, 25(4), 625-638.
[http://dx.doi.org/10.1016/j.bbmt.2018.12.758] [PMID: 30592986]
[34]
Alvi, R.M.; Frigault, M.J.; Fradley, M.G.; Jain, M.D.; Mahmood, S.S.; Awadalla, M.; Lee, D.H.; Zlotoff, D.A.; Zhang, L.; Drobni, Z.D.; Hassan, M.Z.O.; Bassily, E.; Rhea, I.; Ismail-Khan, R.; Mulligan, C.P.; Banerji, D.; Lazaryan, A.; Shah, B.D.; Rokicki, A.; Raje, N.; Chavez, J.C.; Abramson, J.; Locke, F.L.; Neilan, T.G. Cardiovascular events among adults treated with chimeric antigen receptor T-cells (CAR-T). J. Am. Coll. Cardiol., 2019, 74(25), 3099-3108.
[http://dx.doi.org/10.1016/j.jacc.2019.10.038] [PMID: 31856966]
[35]
Lefebvre, B.; Kang, Y.; Smith, A.M.; Frey, N.V.; Carver, J.R.; Scherrer-Crosbie, M. Cardiovascular effects of CAR T-cell therapy. JACC: CardioOncology, 2020, 2(2), 193-203.
[http://dx.doi.org/10.1016/j.jaccao.2020.04.012] [PMID: 32776016]
[36]
Shalabi, H.; Sachdev, V.; Kulshreshtha, A.; Cohen, J.W.; Yates, B.; Rosing, D.R.; Sidenko, S.; Delbrook, C.; Mackall, C.; Wiley, B.; Lee, D.W.; Shah, N.N. Impact of cytokine release syndrome on cardiac function following CD19 CAR-T cell therapy in children and young adults with hematological malignancies. J. Immunother. Cancer, 2020, 8(2), e001159.
[http://dx.doi.org/10.1136/jitc-2020-001159] [PMID: 32883871]
[37]
Burstein, D.S.; Maude, S.; Grupp, S.; Griffis, H.; Rossano, J.; Lin, K. Cardiac profile of chimeric antigen receptor T-cell therapy in children: A single-institution experience. Biol. Blood Marrow Transplant., 2018, 24(8), 1590-1595.
[http://dx.doi.org/10.1016/j.bbmt.2018.05.014] [PMID: 29772353]
[38]
Fitzgerald, J.C.; Weiss, S.L.; Maude, S.L.; Barrett, D.M.; Lacey, S.F.; Melenhorst, J.J.; Shaw, P.; Berg, R.A.; June, C.H.; Porter, D.L.; Frey, N.V.; Grupp, S.A.; Teachey, D.T. Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia. Crit. Care Med., 2017, 45(2), e124-e131.
[http://dx.doi.org/10.1097/CCM.0000000000002053] [PMID: 27632680]
[39]
Kochenderfer, J.N.; Somerville, R.P.T.; Lu, T.; Shi, V.; Bot, A.; Rossi, J.; Xue, A.; Goff, S.L.; Yang, J.C.; Sherry, R.M.; Klebanoff, C.A.; Kammula, U.S.; Sherman, M.; Perez, A.; Yuan, C.M.; Feldman, T.; Friedberg, J.W.; Roschewski, M.J.; Feldman, S.A.; McIntyre, L.; Toomey, M.A.; Rosenberg, S.A. Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T-cells are associated with high serum Interleukin-15 levels. J. Clin. Oncol., 2017, 35(16), 1803-1813.
[http://dx.doi.org/10.1200/JCO.2016.71.3024] [PMID: 28291388]
[40]
Wang, S.Y.; Zhao, L.N.; Cheng, H.; Shi, M.; Chen, W.; Qi, K.M.; Sun, C.; Wang, X.; Cao, J.; Xu, K.L. Long-term safety and activity of humanized CD19 chimeric antigen receptor T cells for children and young adults with relapsed/refractory acute lymphoblastic leukemia. Zhonghua Xue Ye Xue Za Zhi, 2022, 43(7), 557-561.
[PMID: 36709132]
[41]
Lee, D.W.; Kochenderfer, J.N.; Stetler-Stevenson, M.; Cui, Y.K.; Delbrook, C.; Feldman, S.A.; Fry, T.J.; Orentas, R.; Sabatino, M.; Shah, N.N.; Steinberg, S.M.; Stroncek, D.; Tschernia, N.; Yuan, C.; Zhang, H.; Zhang, L.; Rosenberg, S.A.; Wayne, A.S.; Mackall, C.L. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: A phase 1 dose-escalation trial. Lancet, 2015, 385(9967), 517-528.
[http://dx.doi.org/10.1016/S0140-6736(14)61403-3] [PMID: 25319501]
[42]
Davila, M.L.; Riviere, I.; Wang, X.; Bartido, S.; Park, J.; Curran, K.; Chung, S.S.; Stefanski, J.; Borquez-Ojeda, O.; Olszewska, M.; Qu, J.; Wasielewska, T.; He, Q.; Fink, M.; Shinglot, H.; Youssif, M.; Satter, M.; Wang, Y.; Hosey, J.; Quintanilla, H.; Halton, E.; Bernal, Y.; Bouhassira, D.C.G.; Arcila, M.E.; Gonen, M.; Roboz, G.J.; Maslak, P.; Douer, D.; Frattini, M.G.; Giralt, S.; Sadelain, M.; Brentjens, R. Efficacy and toxicity management of 19-28z CAR T-cell therapy in B-cell acute lymphoblastic leukemia. Sci. Transl. Med., 2014, 6(224), 224ra25.
[http://dx.doi.org/10.1126/scitranslmed.3008226] [PMID: 24553386]
[43]
Yáñez, L.; Sánchez-Escamilla, M.; Perales, M.A. CAR T-cell toxicity: Current management and future directions. HemaSphere, 2019, 3(2), e186.
[http://dx.doi.org/10.1097/HS9.0000000000000186] [PMID: 31723825]
[45]
Schuster, S.J.; Bishop, M.R.; Tam, C.S.; Waller, E.K.; Borchmann, P.; McGuirk, J.P.; Jäger, U.; Jaglowski, S.; Andreadis, C.; Westin, J.R.; Fleury, I.; Bachanova, V.; Foley, S.R.; Ho, P.J.; Mielke, S.; Magenau, J.M.; Holte, H.; Pantano, S.; Pacaud, L.B.; Awasthi, R.; Chu, J.; Anak, Ö.; Salles, G.; Maziarz, R.T. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N. Engl. J. Med., 2019, 380(1), 45-56.
[http://dx.doi.org/10.1056/NEJMoa1804980] [PMID: 30501490]
[46]
Maude, S.L.; Laetsch, T.W.; Buechner, J.; Rives, S.; Boyer, M.; Bittencourt, H.; Bader, P.; Verneris, M.R.; Stefanski, H.E.; Myers, G.D.; Qayed, M.; De Moerloose, B.; Hiramatsu, H.; Schlis, K.; Davis, K.L.; Martin, P.L.; Nemecek, E.R.; Yanik, G.A.; Peters, C.; Baruchel, A.; Boissel, N.; Mechinaud, F.; Balduzzi, A.; Krueger, J.; June, C.H.; Levine, B.L.; Wood, P.; Taran, T.; Leung, M.; Mueller, K.T.; Zhang, Y.; Sen, K.; Lebwohl, D.; Pulsipher, M.A.; Grupp, S.A. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med., 2018, 378(5), 439-448.
[http://dx.doi.org/10.1056/NEJMoa1709866] [PMID: 29385370]
[47]
Laetsch, T.W.; Myers, G.D.; Baruchel, A.; Dietz, A.C.; Pulsipher, M.A.; Bittencourt, H.; Buechner, J.; De Moerloose, B.; Davis, K.L.; Nemecek, E.; Driscoll, T.; Mechinaud, F.; Boissel, N.; Rives, S.; Bader, P.; Peters, C.; Sabnis, H.S.; Grupp, S.A.; Yanik, G.A.; Hiramatsu, H.; Stefanski, H.E.; Rasouliyan, L.; Yi, L.; Shah, S.; Zhang, J.; Harris, A.C. Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: A global, single-arm, phase 2 trial. Lancet Oncol., 2019, 20(12), 1710-1718.
[http://dx.doi.org/10.1016/S1470-2045(19)30493-0] [PMID: 31606419]
[48]
Kerr, W.G.; Chisholm, J.D. The next generation of immunotherapy for cancer: Small molecules could make big waves. J. Immunol., 2019, 202(1), 11-19.
[http://dx.doi.org/10.4049/jimmunol.1800991] [PMID: 30587569]
[49]
Kabir, T.F.; Chauhan, A.; Anthony, L.; Hildebrandt, G.C. Immune checkpoint inhibitors in pediatric solid tumors: Status in 2018. Ochsner J., 2018, 18(4), 370-376.
[http://dx.doi.org/10.31486/toj.18.0055] [PMID: 30559623]
[50]
Bosse, K.R.; Majzner, R.G.; Mackall, C.L.; Maris, J.M. Immune-based approaches for the treatment of pediatric malignancies. Annu. Rev. Cancer Biol., 2020, 4(1), 353-370.
[http://dx.doi.org/10.1146/annurev-cancerbio-030419-033436] [PMID: 34113750]
[51]
Love, V.A.; Grabie, N.; Duramad, P.; Stavrakis, G.; Sharpe, A.; Lichtman, A. CTLA-4 ablation and interleukin-12 driven differentiation synergistically augment cardiac pathogenicity of cytotoxic T lymphocytes. Circ. Res., 2007, 101(3), 248-257.
[http://dx.doi.org/10.1161/CIRCRESAHA.106.147124] [PMID: 17569889]
[52]
Nishimura, H.; Okazaki, T.; Tanaka, Y.; Nakatani, K.; Hara, M.; Matsumori, A.; Sasayama, S.; Mizoguchi, A.; Hiai, H.; Minato, N.; Honjo, T. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science, 2001, 291(5502), 319-322.
[http://dx.doi.org/10.1126/science.291.5502.319] [PMID: 11209085]
[53]
Rubio-Infante, N.; Ramírez-Flores, Y.A.; Castillo, E.C.; Lozano, O.; García-Rivas, G.; Torre-Amione, G. Cardiotoxicity associated with immune checkpoint inhibitor therapy: A meta‐analysis. Eur. J. Heart Fail., 2021, 23(10), 1739-1747.
[http://dx.doi.org/10.1002/ejhf.2289] [PMID: 34196077]
[54]
Salem, J.E.; Manouchehri, A.; Moey, M.; Lebrun-Vignes, B.; Bastarache, L.; Pariente, A.; Gobert, A.; Spano, J.P.; Balko, J.M.; Bonaca, M.P.; Roden, D.M.; Johnson, D.B.; Moslehi, J.J. Cardiovascular toxicities associated with immune checkpoint inhibitors: An observational, retrospective, pharmacovigilance study. Lancet Oncol., 2018, 19(12), 1579-1589.
[http://dx.doi.org/10.1016/S1470-2045(18)30608-9] [PMID: 30442497]
[55]
Li, C.; Bhatti, S.A.; Ying, J. Immune checkpoint inhibitors—associated cardiotoxicity. Cancers, 2022, 14(5), 1145.
[http://dx.doi.org/10.3390/cancers14051145] [PMID: 35267453]
[56]
Hu, J.; Tian, R.; Ma, Y.; Zhen, H.; Ma, X.; Su, Q.; Cao, B. Risk of cardiac adverse events in patients treated with immune checkpoint inhibitor regimens: A systematic review and meta-analysis. Front. Oncol., 2021, 11, 645245.
[http://dx.doi.org/10.3389/fonc.2021.645245] [PMID: 34123795]
[57]
Krause, D.S.; Van Etten, R.A. Tyrosine kinases as targets for cancer therapy. N. Engl. J. Med., 2005, 353(2), 172-187.
[http://dx.doi.org/10.1056/NEJMra044389] [PMID: 16014887]
[58]
Kantarjian, H.; Sawyers, C.; Hochhaus, A.; Guilhot, F.; Schiffer, C.; Gambacorti-Passerini, C.; Niederwieser, D.; Resta, D.; Capdeville, R.; Zoellner, U.; Talpaz, M.; Druker, B.; Goldman, J.; O’Brien, S.G.; Russell, N.; Fischer, T.; Ottmann, O.; Cony-Makhoul, P.; Facon, T.; Stone, R.; Miller, C.; Tallman, M.; Brown, R.; Schuster, M.; Loughran, T.; Gratwohl, A.; Mandelli, F.; Saglio, G.; Lazzarino, M.; Russo, D.; Baccarani, M.; Morra, E. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N. Engl. J. Med., 2002, 346(9), 645-652.
[http://dx.doi.org/10.1056/NEJMoa011573] [PMID: 11870241]
[59]
Druker, B.J.; Talpaz, M.; Resta, D.J.; Peng, B.; Buchdunger, E.; Ford, J.M.; Lydon, N.B.; Kantarjian, H.; Capdeville, R.; Ohno-Jones, S.; Sawyers, C.L. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med., 2001, 344(14), 1031-1037.
[http://dx.doi.org/10.1056/NEJM200104053441401] [PMID: 11287972]
[60]
Druker, B.J.; Guilhot, F.; O’Brien, S.G.; Gathmann, I.; Kantarjian, H.; Gattermann, N.; Deininger, M.W.N.; Silver, R.T.; Goldman, J.M.; Stone, R.M.; Cervantes, F.; Hochhaus, A.; Powell, B.L.; Gabrilove, J.L.; Rousselot, P.; Reiffers, J.; Cornelissen, J.J.; Hughes, T.; Agis, H.; Fischer, T.; Verhoef, G.; Shepherd, J.; Saglio, G.; Gratwohl, A.; Nielsen, J.L.; Radich, J.P.; Simonsson, B.; Taylor, K.; Baccarani, M.; So, C.; Letvak, L.; Larson, R.A. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med., 2006, 355(23), 2408-2417.
[http://dx.doi.org/10.1056/NEJMoa062867] [PMID: 17151364]
[61]
Chu, T.F.; Rupnick, M.A.; Kerkela, R.; Dallabrida, S.M.; Zurakowski, D.; Nguyen, L.; Woulfe, K.; Pravda, E.; Cassiola, F.; Desai, J.; George, S.; Harris, D.M.; Ismail, N.S.; Chen, J-H.; Schoen, F.J.; Van den Abbeele, A.D.; Demetri, G.D.; Force, T.; Chen, M.H.; Morgan, J.A. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet, 2007, 370(9604), 2011-2019.
[http://dx.doi.org/10.1016/S0140-6736(07)61865-0] [PMID: 18083403]
[62]
Ewer, M.S.; Suter, T.M.; Lenihan, D.J.; Niculescu, L.; Breazna, A.; Demetri, G.D.; Motzer, R.J. Cardiovascular events among 1090 cancer patients treated with sunitinib, interferon, or placebo: A comprehensive adjudicated database analysis demonstrating clinically meaningful reversibility of cardiac events. Eur. J. Cancer, 2014, 50(12), 2162-2170.
[http://dx.doi.org/10.1016/j.ejca.2014.05.013] [PMID: 24930624]
[63]
Jain, D.; Russell, R.R.; Schwartz, R.G.; Panjrath, G.S.; Aronow, W. Cardiac complications of cancer therapy: Pathophysiology, identification, prevention, treatment, and future directions. Curr. Cardiol. Rep., 2017, 19(5), 36.
[http://dx.doi.org/10.1007/s11886-017-0846-x] [PMID: 28374177]
[64]
Chaar, M.; Kamta, J.; Ait-Oudhia, S. Mechanisms, monitoring, and management of tyrosine kinase inhibitors-associated cardiovascular toxicities. OncoTargets Ther., 2018, 11, 6227-6237.
[http://dx.doi.org/10.2147/OTT.S170138] [PMID: 30288058]
[65]
Motokawa, T.; Ikeda, S.; Ueno, Y.; Eguchi, M.; Minami, T.; Kawano, H.; Kobayashi, K.; Imaizumi, Y.; Maemura, K. Comparison of Dasatinib- and Imatinib-related cardiotoxic adverse events in Japanese patients with chronic myeloid leukemia and gastrointestinal stromal tumor. Circ. Rep., 2022, 4(1), CR-21-CR-0140.
[http://dx.doi.org/10.1253/circrep.CR-21-0140] [PMID: 35083382]
[66]
Casavecchia, G.; Spinosa, G.; De Gennaro, L.; Zicchino, S.; Gravina, M.; Magnesa, M.; Di Biase, M.; Brunetti, N.D. Incidence of cardiovascular events in patients with chronic myeloid leukaemia treated with tyrosine kinase inhibitors. Acta Cardiol., 2022, 77(2), 130-135.
[http://dx.doi.org/10.1080/00015385.2021.1888017] [PMID: 33685352]
[67]
Narayan, H.K.; Sheline, K.; Wong, V.; Kuo, D.; Choo, S.; Yoon, J.; Leger, K.; Kutty, S.; Fradley, M.; Tremoulet, A.; Ky, B.; Armenian, S.; Guha, A. Cardiovascular toxicities with pediatric tyrosine kinase inhibitor therapy: An analysis of adverse events reported to the Food and Drug Administration. Pediatr. Blood Cancer, 2023, 70(2), e30059.
[http://dx.doi.org/10.1002/pbc.30059] [PMID: 36385736]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy